XM does not provide services to residents of the United States of America.

F
F

Fresenius

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 4 weeks ago

Fresenius takes tentative step on road to breakup

BREAKINGVIEWS-Fresenius takes tentative step on road to breakup The author is a Reuters Breakingviews columnist. The opinions expressed are their own. LONDON, Feb 22 (Reuters Breakingviews) - Fresenius’s FREG.DE sprawling business is getting tighter. On Tuesday evening the $17 billion German medical technology company said it will relinquish control of its listed dialysis firm, Fresenius Medical Care FMEG.DE , in order to focus on its core businesses.
C
F
S
F
Reuters - 4 weeks ago

FMC: some care-coordination, product development assets could be sold

FMC: some care-coordination, product development assets could be sold FRANKFURT, Feb 22 (Reuters) - Fresenius Medical Care FMEG.DE is looking into the potential sale of certain care-coordination services units that are not closely related to its core dialysis business as well as certain medical device development assets to cut debt, its CEO said. CEO Helen Giza told a media briefing that she was "looking into whether these businesses are as close to the core as we would like".
F
F
Reuters - 4 weeks ago

Rate-hike fears dent European shares ahead of U.S. Fed minutes

UPDATE 2-Rate-hike fears dent European shares ahead of U.S. Fed minutes For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window BESI jumps as Q4 revenue beats estimate on strong orders Stellantis tops forecasts in H2, shares up Fresenius' shares fall on 2023 profit warning U.S. Fed minutes eyed for later in the day STOXX 600 off 0.3% Adds details and updates prices to close By Shreyashi Sanyal and Bansari Mayur Kamdar Feb 22 (Reuters) - European
F
H
F
E
F
U
G
Reuters - 4 weeks ago

Germany's FMC buoyed by Fresenius plan to cede control

UPDATE 4-Germany's FMC buoyed by Fresenius plan to cede control FMC up 12.1%, Fresenius shares drop 3% Fresenius to give up strategic control over FMC Fresenius plans no sale of 32% stake in FMC Investors say sale is possible eventually CEO says new legal form offers option to divest Adds CEO comment By Ludwig Burger and Patricia Weiss BAD HOMBURG, Germany, Feb 22 (Reuters) - Fresenius Medical Care FMEG.DE shares hit their highest level in nearly seven months on Wednesday, welcoming news that FM
E
F
S
F
G
Reuters - 4 weeks ago

Fresenius shares down 3.1% after group flags 2023 profit fall

Fresenius shares down 3.1% after group flags 2023 profit fall BERLIN, Feb 22 (Reuters) - Shares in Fresenius SE FREG.DE fell by 3.1% early Wednesday after the German healthcare group forecast a 2023 fall in profit partly due to plans to cede strategic control over dialysis group Fresenius Medical Care (FMC) FMEG.DE . Shares in FMC were up by 5.6%.
F
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.